This page lists all pharmaceutical reports related to the field of Metabolic & Hormonal Disorders. The reports include market research reports and pipeline analyses.
Displaying 101 - 131 of 131 results
- Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
- Contraceptives Market to 2016 - Demand for Long Acting Birth Control Pills Encourages Growth in Hormonal Contraceptives Market
- The Future of In Vitro and In Vivo Diagnostic Integration
- Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
- Pharmaceutical Key Trends 2011 – Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
- Pharmaceutical Key Trends 2011 – Biosimilar Market Overview: Biosimilar uptake set to accelerate
- R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment
- Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
- Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
- Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
- Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
- Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
- Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies
- Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
- Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future
- GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
- Post-Menopausal Hormone Replacement Therapy (HRT) - Pipeline Assessment and Market Forecasts to 2018
- Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Uterine Fibroids Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Acromegaly and Gigantism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Women’s Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Hyperparathyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018
- Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Dyslipidemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Type 1 Diabetes Therapeutics - Pipeline Assessment and Market Forecasts to 2018